What’s Ahead For CAR-T Play Kite Pharma? – Seeking Alpha
FierceBiotech |
What’s Ahead For CAR–T Play Kite Pharma?
Seeking Alpha Also a CAR–T therapy, KITE-585 is being evaluated for the treatment of multiple myeloma (plasma cell cancer) through the targeting of B-cell maturation antigen (BCMA), which has been implicated in other lymphomas and leukemia. The company expects to … The FDA priority review gives Kite’s CAR–T a PDUFA date of November 29FierceBiotech |
|
Taconic Biosciences Licenses CRISPR IP From ERS Genomics
GenomeWeb NEW YORK (GenomeWeb) – Taconic Biosciences has signed a license agreement with ERS Genomics to use ERS’ CRISPR-Cas9 technology to generate unique murine models. Under the agreement, Taconic receives a worldwide, non-exclusive license to … Taconic Biosciences Secures CRISPR License From ERS GenomicsThe News Reports |
Gizmodo |
CRISPR May Not Be Nearly as Precise as We Thought
Gizmodo The revolutionary gene-editing technology CRISPR-Cas9 is often described as “molecular scissors” for its ability to turn previously improbable feats of genetic engineering into exercises in cutting and pasting. But while over the last few years CRISPR … Crack in CRISPR Facade after Unanticipated In Vivo Mutations AriseGenetic Engineering & Biotechnology News CRISPR Gene-Editing Can Cause Hundreds of Unexpected MutationsScienceAlert Boom in human gene editing as 20 CRISPR trials gear upNew Scientist Futurism –Siliconrepublic.com –Cosmos all 22 news articles » |